Statement: locally advanced carcinoid tumor is a carcinoid tumor that has spread to nearby tissues or lymph nodes. Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 17/65 (26.15%)   Febrile neutropenia 3/65 (4.62%)   Neutropenia 2/65 (3.08%)   Pancytopenia 1/65 (1.54%)   Thrombocytopenia 1/65 (1.54%)   Cardiac arrest 2/65 (3.08%)   Myocardial infarction 1/65 (1.54%)   Diarrhoea 5/65 (7.69%)   Stomatitis 1/65 (1.54%)   Vomiting 2/65 (3.08%)   Fatigue 1/65 (1.54%)   Jaundice 1/65 (1.54%)   Neutropenic infection 2/65 (3.08%)
Secondary_evidence: Adverse Events 1:   Total: 173/472 (36.65%)   Anaemia 6/472 (1.27%)   Febrile neutropenia 4/472 (0.85%)   Iron deficiency anaemia 1/472 (0.21%)   Leukopenia 2/472 (0.42%)   Neutropenia 2/472 (0.42%)   Thrombocytopenia 4/472 (0.85%)   Acute myocardial infarction 1/472 (0.21%)   Aortic valve incompetence 0/472 (0.00%)   Atrial fibrillation 2/472 (0.42%)   Cardiac arrest 1/472 (0.21%) Adverse Events 2:   Total: 40/238 (16.81%)   Anaemia 0/238 (0.00%)   Febrile neutropenia 1/238 (0.42%)   Iron deficiency anaemia 0/238 (0.00%)   Leukopenia 0/238 (0.00%)   Neutropenia 2/238 (0.84%)   Thrombocytopenia 0/238 (0.00%)   Acute myocardial infarction 0/238 (0.00%)   Aortic valve incompetence 1/238 (0.42%)   Atrial fibrillation 0/238 (0.00%)   Cardiac arrest 0/238 (0.00%)